Publication

Biodistribution and PET Imaging of Labeled Bispecific T Cell-Engaging Antibody Targeting EpCAM

Warnders, F. J., Waaijer, S. J. H., Pool, M., Lub-de Hooge, M. N., Friedrich, M., Terwisscha van Scheltinga, A. G. T., Deegen, P., Stienen, S. K., Pieslor, P. C., Cheung, H. K., Kosterink, J. G. W. & de Vries, E. G. E., May-2016, In : Journal of Nuclear Medicine. 57, 5, p. 812-817 6 p.

Research output: Contribution to journalArticleAcademicpeer-review

Copy link to clipboard

Documents

  • Biodistribution and PET Imaging of Labeled Bispecific T Cell-Engaging

    Final publisher's version, 1 MB, PDF document

DOI

AMG 110, a bispecific T cell engager (BITE) antibody construct, induces T cell-mediated cancer cell death by cross-linking epithelial cell adhesion molecule (EpCAM) on tumor cells with a cluster of differentiation 3 epsilon (CD3 epsilon) on T cells. We labeled AMG 110 with Zr-89 or near infrared fluorescent dye (IRDye) 800CW to study its tumor targeting and tissue distribution. Methods: Biodistribution and tumor uptake of Zr-89-AMG 110 was studied up to 6 d after intravenous administration to nude BALB/c mice bearing high EpCAM-expressing HT-29 colorectal cancer xenografts. Tumor uptake of Zr-89-AMG 110 was compared with uptake in head and neck squamous cell cancer FaDu (intermediate EpCAM) and promyelocytic leukemia HL60 (EpCAM-negative) xenografts. Intratumoral distribution in HT-29 tumors was studied using 800CW-AMG 110. Results: Tumor uptake of Zr-89-AMG 110 can be clearly visualized using small-animal PET imaging up to 72 h after injection. The highest tumor uptake of Zr-89-AMG 110 at the 40-mu g dose level was observed at 6 and 24 h (respectively, 5.35 +/- 0.22 and 5.30 +/- 0.20 percentage injected dose per gram; n = 3 and 4). Tumor uptake of Zr-89-AMG 110 was EpCAM-specific and correlated with EpCAM expression. 800CW-AMG 110 accumulated at the tumor cell surface in viable EpCAM-expressing tumor tissue. Conclusion: PET and fluorescent imaging provided real-time information about AMG 110 distribution and tumor uptake in vivo. Our data support using Zr-89 and IRDye 800CW to evaluate tumor and tissue uptake kinetics of bispecific T cell engager antibody constructs in preclinical and clinical settings.

Original languageEnglish
Pages (from-to)812-817
Number of pages6
JournalJournal of Nuclear Medicine
Volume57
Issue number5
Publication statusPublished - May-2016

ID: 31274039